Ark Therapeutics Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ark Therapeutics Group plc
Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?
Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.
Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
Abbott says DexCom’s patent suits involve technology that was already the subject of a settlement, and raise venue questions.
- In Vitro Diagnostics
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule